论文部分内容阅读
目的探讨急性胃炎患者应用阿托品联合奥美拉唑和山莨岩碱联合奥美拉唑疗效对比,评估其临床意义。方法选择2012年11月~2014年12月我院收诊并行240例急性胃炎患者,随机平均分为观察组(阿托品联合奥美拉唑治疗组)120例和对照组(山莨岩碱联合奥美拉唑治疗组)120例,观察比较两组患者治疗前后临床疗效及不良反应发生情况。结果果两组患者治疗后病情较治疗前明显改善,且观察组治疗的总有效率显著高于对照组,观察组改善程度明显优于对照组(P<0.05);观察组患者临床不良反应的发生率明显较对照组低,差异具有统计学意义(P<0.05)。结论急性胃炎患者应用阿托品联合奥美拉唑较比应用山莨岩碱联合奥美拉唑治疗更安全可行,临床疗效显著,值得推广应用。
Objective To investigate the clinical efficacy of atropine in combination with omeprazole and acerolazoline in combination with omeprazole in patients with acute gastritis. Methods A total of 240 patients with acute gastritis admitted to our hospital from November 2012 to December 2014 were randomly divided into observation group (atropine plus omeprazole treatment group) and control group (acrolein combined with Austria Melazol treatment group) 120 cases were observed and compared between the two groups before and after treatment of clinical efficacy and adverse reactions. Results The two groups of patients after treatment significantly improved the condition than before treatment, and the observation group the total effective rate was significantly higher than the control group, the observation group was significantly better than the control group (P <0.05); clinical adverse reactions in the observation group The incidence was significantly lower than the control group, the difference was statistically significant (P <0.05). Conclusion The application of atropine and omeprazole in patients with acute gastritis is safer and more effective than the application of scutellar base combined with omeprazole. The clinical effect is significant and should be popularized and applied.